Compare AbbVie Inc (ABBV) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Prudential PLC — how do they compare? AbbVie Inc trades at $249.94 (market cap $441.94B), while Prudential PLC trades at $27.69 (market cap $34.02B). The key difference: AbbVie Inc is far larger — about 13× Prudential PLC's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | PUK | |
|---|---|---|
Market Cap | $441.94B | $34.02B |
Sector | Health | Financials |
52-Week High | $263.58 | $33.61 |
52-Week Low | $197.38 | $24.98 |
Enterprise Value | $506.19B | $35.46B |
Dividend Yield | 2.77% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Prudential PLC (PUK) trades at $28.22, down 0.21% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The stock shows strong fundamentals with a P/E of 8.92, net income margin of 14.52%, and ROE of 21.15%. Recent earnings beat expectations in Q4 2025, and cash flow from operations reached $3.61B in 2024. However, news of China taxing offshore insurance policies caused a recent sell-off, highlighting regulatory risks.
The outlook for PUK is mixed; solid profitability and low valuation metrics provide upside potential, supported by a 50% analyst buy rating. Key risks include exposure to Chinese regulatory changes and competitive pressures in Asia. Earnings growth and strategic focus on capital-light operations are catalysts, but investor sentiment remains cautious due to near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
